SCHEMBL1761820

SCHEMBL1761820

CC(C)[C@H](NC(=O)c1ccc(-c2ccc(Nc3nc4ccccc4s3)cc2)cc1Cl)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.60
CSGALNACT1 Q8TDX6 2/20 0.60
DHODH Q02127 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MAPT P10636 3/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
SCD O00767 1/20 0.43
FFAR2 O15552 1/20 0.43
POLB P06746 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
LCK P06239 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1761408 0.90 DGAT1 (0.64) DGAT1CSGALNACT1DHODHSMN1; SMN2NPC1
SCHEMBL1761730 0.90 DGAT1 (0.63) DGAT1CSGALNACT1SMN1; SMN2NPC1RAB9A
SCHEMBL1761401 0.89 DGAT1 (0.63) DGAT1CSGALNACT1DHODHSMN1; SMN2NPC1
SCHEMBL1761431 0.89 DGAT1 (0.53) DGAT1CSGALNACT1KMT2ALCK
SCHEMBL1761396 0.89 DGAT1 (0.77) DGAT1CSGALNACT1SMN1; SMN2NPC1RAB9A
SCHEMBL1761827 0.88 DGAT1 (0.58) DGAT1CSGALNACT1SMN1; SMN2NPC1RAB9A
SCHEMBL1761317 0.87 DGAT1 (0.55) DGAT1CSGALNACT1KMT2A
SCHEMBL1761825 0.86 DGAT1 (0.75) DGAT1CSGALNACT1SMN1; SMN2NPC1RAB9A
SCHEMBL1761505 0.86 DGAT1 (0.75) DGAT1CSGALNACT1SMN1; SMN2NPC1RAB9A
SCHEMBL3389668 0.83 DGAT1 (0.50) DGAT1CSGALNACT1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118302-A1 PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2011-05-19 US claimed
EP-1805156-B1 PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER HEALTHCARE LLC (US) 2010-12-22 EP claimed
US-7759376-B2 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity BAYER HEALTHCARE LLC (US) 2010-07-20 US claimed
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2007-11-15 US claimed
EP-1805156-B1 PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER HEALTHCARE LLC (US) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity FABP4, GPR119, PGC DGAT1 486/4885CSGALNACT1 3157/4885DHODH 2149/4885
US-20110118302-A1 PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY FABP4, GPR119, PGC DGAT1 486/4885CSGALNACT1 3157/4885DHODH 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.